Sihuan Pharmaceutical Holdings Group Ltd. · HKEX:460
Sihuan Pharmaceutical — FY2022 Earnings Presentation
48 slides from Sihuan Pharmaceutical's earnings presentation, March 2023
Slide 1: 2022 Annual Results Presentation
Sihuan Pharmaceutical Holdings Group Ltd. 四环医药控股集团有限公司 (incorporated in Bermuda with limited liability) （于百慕达注册成立之有限公司) Stock Code 股份代号：0460 Building China’s Leading Medical Aesthetic and Biopharmaceutical Company with Rigor and Innovation of a Pharmaceutical Company 2022 Annual Results Presentation
Slide 2: Disclaimer
Disclaimer The sole purpose of this Presentation (the “Presentation”) is to assist the recipient in deciding whether it wishes to proceed with a further investigation of Sihuan Pharmaceutical Holdings Group Ltd. (the “Company”) and it is not intended to form the basis of any decision to purchase sec
Slide 3: Promoting Sihuan Pharmaceutical's 2.0 version in full speed
Promoting Sihuan Pharmaceutical’s 2.0 version in full speed Becoming a leading medical aesthetic and innovative pharmaceutical company with industrial upgrading and development Category 01 02 03 04 05 Company Overview Pharmaceutical Medical Aesthetic Financial Review Appendix Business Review Busines
Slide 4: Building China's Leading Medical Aesthetic and Biopharmaceutical Company
Building China’s Leading Medical Aesthetic and Biopharmaceutical Company with Rigor and Innovation of a Pharmaceutical Company Promoting Sihuan Pharm’s 2.0 version in full speed, Transforming into a leading medical aesthetic and innovative pharmaceutical company API 20+ high-end specialty APIs, Disp
Slide 5: 2022 Milestones
2022 Milestones 2022.1-2023.2 Generic medicine and others 2022.4 2022.9 2022.12 2023.1 • Exclusively distributed Korean hyaluronic • Proposed spin-off on STAR Market of • Completed round A+ financing of • Kelinao® (Cinepazide maleate injection) acid PersnicaTM was approved SSE and application was ac
Slide 6: Investment Highlights
Investment Highlights Sihuan Pharm owns: Strong R&D platform and capabilities MeiYan KongJian Xuanzhu Biopharm Huisheng Biopharm Generic Medicine Two R&D centers in China and the U.S., Owns both small and large molecule R&D One of the few biopharmaceutical leaders Beijing Aohe Research Institute con
Slide 7: Development Goals and Strategies
Development Goals and Strategies Building China’s Leading Medical Aesthetic and Biopharmaceutical Company Medical Pharmaceutical Aesthetic Generic/MCM/Industria l Hemp/API/CDMO MeiYan KongJian Xuanzhu Biopharm Huisheng Biopharm “Star” business of the Becoming China’s leading Building a leading Gradu
Slide 8: 40+ Medical Aesthetic Products & 60+ Innovative/Biology Drugs
40+ Medical Aesthetic Products & 60+ Innovative/Biology Drugs Building China’s Leading Medical Aesthetic and Biopharmaceutical Company Segment Subsidiary Business Category Product name Pre-clinical Clinical Registration Launch Collegen complex filler（Class III） Filler PLLA filler（Class III） PCL fill
Slide 9: Three Capabilities of Registration, Production and Sales
Three Capabilities of Registration,Production and Sales Facilitating and accelerating the commercialisation of quality product pipelines Sihuan Pharm has strong registration, production and sales capacity, which can ensure the rapid industrialization of new products after approval Registr Product Sa
Slide 10: Pharmaceutical Business
Pharmaceutical Business Successfully transformed from a generic to a biopharmaceutical company Upgrade and develop into a leading biopharmaceutical company in China at full speed
Slide 11: Pharmaceutical Business Overview
Pharmaceutical Business Overview Successfully transformed from a generic to a biopharmaceutical company to upgrade and develop into a leading biopharmaceutical company in China at full speed China's leading independent R&D platform One of the few leading biopharmaceutical for innovative drugs with t
Slide 12: Xuanzhu Biopharm
Pharmaceutical Segment Xuanzhu Biopharm China's leading innovative biological drug R&D platform
Slide 13: Investment Highlights
Investment Highlights One of the most complete pipeline layout in breast cancer, with independently R&D capabilities in both small and large molecules R&D Capability Product Pipeline Rich R&D pipeline focusing on therapeutic areas The most complete pipeline layout on with significant clinical needs
Slide 14: Business Developments
Business Developments Multiple products reached positive clinical progress, promote spin-off listing on STAR Market rapidly 2022 Mar 2022 May 2022 June 2022 July HKEX approved to spin off The highly active and selective Xuanzhu Biopharm entered into an Anaprazole sodium was Xuanzhu Biopharm and to A
Slide 15: 25+ Drugs under R&D with Comprehensive Layout in Breast Cancer
25+ Drugs under R&D with Comprehensive Layout in Breast Cancer for Main Targets Focus on areas including oncology, NASH and digestion, with a established and balanced short- to long-term pipeline of sustained innovation Therapeutic Area Target Drug Name Indications Clinical Pre-clinical IND NDA Phas
Slide 16: Huisheng Pharm
Pharmaceutical Segment Huisheng Pharm Leading biopharmaceutical company with full product coverage in diabetes and complications
Slide 17: Investment Highlights
Investment Highlights Huisheng Pharm: One of the biopharm leaders in China with full product coverage in diabetes and complications Innovative Target Drugs 1 Huge market potential in China GLP-1 SGLT-2 inhibitor 2 Rich product pipeline • Semaglutide Injection • Janagliflozin (Class 1 new drug) • Sem
Slide 18: Business Developments
Business Developments 2022 Jan 2022 June 2022 Dec Completed round A financing Phase I biological base is Insulin aspart, insulin of RMB500 million, the post- under expansion aspart 30 and insulin aspart investment valuation reached 50, NDA accepted Phase II biological base almost RMB5.0 billion comp
Slide 19: Rich Product Pipeline, Full Coverage in Diabetes and Complications
Rich Product Pipeline, Realize Full Coverage in Areas of Diabetes and Complications Covering 2nd, 3rd, new generation insulin and analogues, GLP-1, SGLT-2 and complications R&D Stage Category Category Products Pre-clinical IND Phase I Phase II Phase III NDA Janagliflozin Oral Class 1 new drug Janagl
Slide 20: Production Facilities Built to International Standards
Production Facilities are Designed, Built and Operated with International Standard to International Standards Existing capacity exceeds 10 million units, and can exceed 100 million unit after the construction of phase II base is finished, ranking top in China Phase I and II Biological Bases: annual
Slide 21: Generic/MCM/Industrial Hemp/API/CDMO
Pharmaceutical Segment Generic/MCM/Industrial Hemp/API/CDMO Solid“Cash Cow”
Slide 22: Rapid Product Launch Based on Three Core Competencies
Rapid Product Launch Based on Three Core Competencies: Registration, Production and Sales 3 drugs included in NRDL 2022, Kelinao® was removed from the key monitoring list, "cash cow" business continues to generate solid cash flow Rich high-end generics medicine Strong product registration and High-e
Slide 23: MeiYan KongJian
Sihuan Medical Aesthetic MeiYan KongJian Building China’s leading medical aesthetic company 23
Slide 24: Investment Highlights
Investment Highlights Sihuan Medical Aesthetic MeiYan KongJian: Building a leading medical aesthetic company of full product matrix with rigor and innovation of a pharmaceutical company Rich product pipeline covering Strong China and overseas R&D team life-cycle needs of beauty lovers to promote pro
Slide 25: Build a complete medical aesthetic product matrix
Build a complete medical aesthetic product matrix through strong in-house R&D and BD capabilities Covering the whole life cycle needs of beauty seekers Business Category Product Name Pre-clinical Clinical Registration Market Launch Collegen complex filler (class III） Filler PLLA filler（class II） PCL
Slide 26: 10+ class III, 20+ class II self-developed products
Multiple self-developed new products to be launched in three years, forming a strong product matrix Established a R&D center in the US to tackle new technology, with strong self-development capability in medical aesthetic products R&D products 10+ class III Approved products 20+ class II including：
Slide 27: Experienced Sales Team and Nationwide Sales Network
Experienced Sales Team and Nationwide Sales Network Further upgrade team structure, optimize strategy, enhance seals capability and services Sales Center 3,500+ medical aesthetic institution coverage Medicalg Sales Sales Marketing Dept Dept I Dept II Dept 100% top 500 institution coverage 310 Brandi
Slide 28: 2022 Annual Financial Review
2022 Annual Financial Review
Slide 29: 2022 Annual Financial Review
2022 Annual Financial Review Continued large R&D investment to further focus on the innovative drug segment and promote the development of two innovative biologics platforms Revenue from Medical Revenue from Innovative and Revenue from Generic Total Revenue R&D Expenses Aesthetic Other Medicine (CDM
Slide 30: R&D expenses: RMB0.94 bil, 42.9% of Total Revenue
R&D expenses: RMB0.94 bil, 42.9% of Total Revenue Significant R&D investment drives large increase in the value of R&D segment and accelargelerates the transformation of pharmaceutical segment to BioPharma innovation Due to the impact that Continuous investment in RMB mil the epidemic has R&D to dev
Slide 31: Solid financial position: cash and financial products of RMB4.79 billion
Solid financial position: maintained cash on hand plus financial products totaling RMB4.79 billion at year end Achieve net operating cash inflows in Generic, medical aesthetics and innovative pharmaceuticals business segments, pay dividends of RMB1.32 billion during 2022 RMB mil Ø Net cash inflow fr
Slide 32: Performance summary
Performance summary： Accelerate innovation transformation and lighten up with further focus on medical aesthetics and innovative drug development Innovative 2022 Segment Information Medical medicine & Generic Cash and cash Total (RMB mil） Aesthetic Others (API & medicine equivalents CDMO) Revenue 15
Slide 33: Appendix
Appendix
Slide 34: Company Milestones
Company Milestones • Established JV with CROMA- • Letybo was launched to market Pharma to expand into • The first independent R&D medical • Signed exclusive China’s medical aesthetic aesthetic product PLLA gel was distribution agreement with market approved South Korean Hugel Inc. on • Acquired Amer
Slide 35: Main product: Letybo
Main product Letybo®（Letybo 100U/50U） Anti-aging product: short course of treatment, quick effect, short repair period for minimally invasive wound, the fourth Botulinum toxin type A launched in China Letybo is positioned as cost-effective and high-quality, which is much higher than the industry req
Slide 36: Main product: Persnica
Main product PersnicaTM Hyaluronate gel: good support, non-spreading displacement, uniform metabolism, long-lasting shaping, high viscosity value, high cross-linking degree and high shaping capacity One of the most popular hyaluronic acid filler brands in South Korea, can be used with Letybo® from t
Slide 37: Main product: Lipivage fat harvesting system
Main product Lipivage® fat harvesting system Innovative fat harvesting system, with independent and ready-to-use two-step fat harvesting, cleaning and transferal system Innovative technology improves the survival rate of fat transplantation to 80%-90% China’s body contouring market is Highly innovat
Slide 38: Main product: PHA microspheres
Main product PHA microspheres and biomanufacturing-based regenerative medical materials PHA is a natural polyester, can be used in regenerative injection products, is a good choice for light medical aesthetics as a new material Sihuan Pharmaceutical’s MeiYan KongJian and Bluepha to establish JV, to
Slide 39: Main Product: Birociclib
Main Product Birociclib • A blockbuster product for HR+/HER2- advanced breast cancer (ABC）patients, an innovative drug of CDK4/6 inhibitor was developed by the company independently, with patents in China, the United States, Europe, Japan and Korea • First and fastest follower of the best-in-class p
Slide 40: Main Product: XZP-KM257
Main Product XZP-KM257 • KM257 is a HER2 bispecific antibody(BsAb), independently developed by Xuanzhu Biopharm technology platform with independent intellectual property rights, with better molecular design, better stability and stronger anti-tumor efficacy, for HER2+ patients with high expression,
Slide 41: Main Product: XZP-KM501 ADC
Main Product XZP-KM501 ADC • KM501-ADC is a HER2 BsAb ADC, which is a modification of KM-257, therefore, it has many advantages of KM-257, used for patients with HER2+ medium and low expression solid tumors (such as breast cancer, gastric cancer, lung cancer, etc.) • The first BsAb ADC to apply for
Slide 42: Main Product: Anaprazole Sodium
Main Product Anaprazole Sodium • The first and the only innovative PPI independently developed in China, with independent intellectual property rights, a new generation, with large market scale, the PPIs sale was nearly RMB 20 billion in 2021 in China • Has the clinical advantage of low risk of drug
Slide 43: Main Product: XZB-0004
Main Product XZB-0004 • Authorized cooperation with SignalChem, to introduce the exclusive development and commercialization rights of the drug in Greater China • An oral small molecule AXL inhibitor with high selectivity, high efficacy and low side effects, a new target for cancer therapy • Compare
Slide 44: Main Product: XZP-001-003 (Molecular Glue)
Main Product XZP-001-003(Molecular Glue) • Three targeted protein molecular glue degrader (MGD) drugs, are developed in cooperation with HB Therapeutics of the United States, with the potential of first in class • It has the characteristics of small weight, easy optimization of physical and chemical
Slide 45: Main Product: Janagliflozin
Main Product Janagliflozin • An innovative drug of SGLT-2 inhibitor, independently developed by the company, with patents in China and other major countries or regions. • A new non-insulin-dependent hypoglycemic drug, which can be used alone or in combination with other drugs, with wide market appli
Slide 46: Main Product: Insulin Degludec
Main Product Insulin Degludec Injection, Insulin Degludec and Insulin Aspart Injection, Insulin Degludec and Liraglutide Injection • A new generation of long-acting insulin analogs with unique long-acting mechanism, excellent hypoglycemic effect and low risk of hypoglycemia. Combination of Insulin D
Slide 47: Main Product: Semaglutide
Main Product Semaglutide • Semaglutide is a once-week GLP-1RA for the treatment of T2DM, and semaglutide tablet is the only oral formulation of GLP-1RA in the world • Multiple advantages have been recognized, and the recommendation level of authoritative guides has been improved. GLP-1RA has advanta
Slide 48: Thank you!
Thank you！ Investor Relations Department Sihuan Pharmaceutical ir.sihuanpharm.com E: ir@sihuanpharm.com
Sihuan Pharmaceutical Holdings Group — FY2022 Earnings Presentation on 6ix